Martin Zapata Laguado, Clinical Oncologist at the National Cancer Institute E.S.E., shared on X:
“ASCO 2025 update data on KN564 maintain benefit on OS, all patients in the trial benefit from Pembrolizumab adjuvant, however we lack more biomarkers perhaps a measure in KIM1 would be outstanding.”
